The Study of Sarcopenia and Aging Biomarkers by the Metabolomics
Status
Conditions
Treatments
Details and patient eligibility
About
With the rapid growth of the global elderly population, the studies of the biomarkers of the sarcopenia and aging are under investigation in different ways. The investigators use Metabolomics to explore the biomarkers of the sarcopenia and aging of the senior adults.
Full description
Metabolomics is the emerging platform technology to address the complexity of a living system. In translational research, metabolomics approaches may enable the detection of multiple disease risk factors and interactions, disease progression, and response of patients to a particular therapy with or without side effects. Metabolomics may provide comprehensive information and improve diagnosis and prognosis which are particularly promising in human complex degenerative diseases. The investigators use Metabolomics to explore the biomarkers of the sarcopenia and aging of the senior adults.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- residents of the Chang Gung Health and Culture Village
- mostly independent and do not require nursing assistance
- capable of managing their daily living activities
- aged ≧ 60
Exclusion criteria
- None.
Trial contacts and locations
Loading...
Central trial contact
Chih-Ming Lin, M.D.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal